Your Liver Got a New Name — And It Changes Everything We Thought We Knew

For years, the term that sat quietly in ultrasound reports and doctor's notes was NAFLD — non-alcoholic fatty liver disease. It told patients, essentially, that fat had accumulated in their liver, and that alcohol wasn't to blame. It was a definition built around what the condition wasn't, rather than what it actually was. In 2023, that changed. A landmark global consensus — led by the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), and their Latin American counterpart — retired NAFLD and gave this condition a new identity: MASLD. Metabolic dysfunction-associated steatotic liver disease.

The new name is a mouthful. But every word in it is doing important work

Why NAFLD Had to Go

The problem with NAFLD was baked into its structure. The medical term non-alcoholic fatty liver disease was coined in 1986 for a condition that has since become the most prevalent liver disorder worldwide. But naming a disease by what it isn't — non-alcoholic — was always medically imprecise, and over time, it became quietly harmful. ScienceDirect

It told patients their liver was "fatty," which carried stigma, implying a failure of discipline or diet. It defined the condition in opposition to alcohol-related liver disease, suggesting these were the only two options. And critically, it said nothing about the underlying mechanisms actually driving the fat accumulation in the first place.

The term MASLD was introduced in 2023 to replace NAFLD, introducing changes in diagnostic criteria and underscoring the direct link between cardiometabolic risk and this prevalent liver disease. The new name also retired "fatty" — a term widely considered stigmatising — replacing it with steatotic, the precise clinical term for fat accumulation in liver cells. nih

Alongside the shift from NAFLD to MASLD came a parallel rename: non-alcoholic steatohepatitis (NASH) became metabolic dysfunction-associated steatohepatitis (MASH). A new category, MetALD, was also created for patients who meet criteria for MASLD but also consume increased amounts of alcohol. The architecture of liver disease classification finally began to reflect biological reality.

The Word That Changes Everything: Metabolic

Pull apart the new acronym and there it is — metabolic dysfunction — sitting at the very front, before liver, before steatotic, before everything. That placement is intentional. It is a declaration of cause.

The new nomenclature recognises metabolic dysfunction as the central driver of the disease, acknowledging the contribution of cardiometabolic risk factors to its pathogenesis. PubMed Central

MASLD encompasses patients who have hepatic steatosis and at least one of five cardiometabolic risk factors. These include overweight or obesity, elevated blood sugar or type 2 diabetes, high blood pressure, high triglycerides, or low HDL cholesterol. Meeting even one of these criteria, alongside confirmed liver steatosis, now defines the condition. This is significant — it captures far more people than the previous framework did, and it points treatment squarely at the metabolic root rather than just the liver symptom

At the cellular level, insulin resistance is a central driver of disease progression, closely linked to obesity and metabolic syndrome. When cells stop responding effectively to insulin, the liver becomes a dumping ground for excess fat it cannot process — and that fat accumulation is the beginning of a cascade that, left unaddressed, can move toward inflammation, fibrosis, cirrhosis, and even liver cancer.

MASLD Has Many Drivers — Not Just What You Eat

Here is where the conversation needs to expand, urgently. The popular image of a fatty liver as a problem caused purely by overeating or drinking is reductive, and the science no longer supports it.

MASLD can also be observed in lean patients with diverse triggers — including high-fructose or high-fat intake, congenital lipodystrophy, genetic causes, or endocrine disorders. This matters because thin individuals with MASLD are routinely missed, their liver health never flagged because their body weight appears unremarkable.

The factors that drive the development of MASLD include not only cardiometabolic risk factors but also genetic polymorphisms, epigenetic alterations, and the gut microbiome. Specific genes — including PNPLA3 and TM6SF2 — create inherited susceptibility, meaning some individuals accumulate liver fat under dietary and lifestyle conditions that would leave others unaffected. PubMed Central

Patients with MASLD often show an altered ratio of gut bacteria, which is correlated with hepatic steatosis and obesity, indicating gut dysbiosis as a significant contributor. An unhealthy gut microbiome increases intestinal permeability, drives systemic inflammation, and worsens liver fat accumulation — independent of how much someone weighs or what they eat in a single day. PubMed Central

The "multiple hit model" of MASLD development involves fat accumulation, insulin resistance, gut dysbiosis, and genetic and environmental elements disrupting the gut-liver axis, leading to impaired intestinal barrier function and increased gut permeability. Poor sleep, chronic stress, sedentary behaviour, ultra-processed food, environmental toxins — all of these contribute hits. No single factor owns this disease. PubMed Central

What Renaming MASLD Means for Your Health

The liver is a remarkably resilient organ — it is also one of the most silently suffering. MASLD produces no symptoms in its early stages. By the time someone feels anything, the disease may already be well advanced. This is why the name change matters clinically: experts argue that framing the condition as a multisystem endocrine-metabolic disorder could improve awareness among clinicians, encourage earlier diagnosis, and expand treatment approaches beyond a narrow focus.

For patients, it should open a different conversation entirely — one that centres metabolic health, gut health, and the interplay of genetics, lifestyle, and environment, rather than simply instructing someone to "eat less fat." The liver is not failing in isolation. It is responding to a whole-body metabolic story that, with the right lens, can finally be read clearly.

MASLD doesn't just rename a disease. It reframes the question we should all be asking — not what is wrong with your liver, but what is the metabolic environment your liver is living in?

That is the question worth answering.